We are live on ! Find out more
APTO

Aptose Biosciences, Inc.
APTO

Delisted

APTO was delisted on the 1st of April, 2025.

Back to rankings

52 hedge funds and large institutions have $39M invested in Aptose Biosciences, Inc. in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

976% more call options, than puts

Call options by funds: $269K | Put options by funds: $25K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less capital invested

Capital invested by funds: $42.6M → $39M (-$3.6M)

10% less funds holding

Funds holding: 58 → 52 (-6)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
0.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
7
Increased
11
Reduced
14
Closed
13
Calls
$269K
Puts
$25K
Net Calls
+$244K
Net Calls Change
+$149K

Top Buyers

Rank Fund Capital Flow
1
SMH
Sanders Morris Harris
Texas
+$468K
2
PM
Precept Management
Texas
+$279K
3
SPC
Sigma Planning Corp
Michigan
+$275K
4
AC
Annandale Capital
Texas
+$246K
5
CC
Carlson Capital
Texas
+$202K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$2.73M
2
Morgan Stanley
Morgan Stanley
New York
-$564K
3
Man Group
Man Group
United Kingdom
-$472K
4
Millennium Management
Millennium Management
New York
-$388K
5
NCM
Nantahala Capital Management
Connecticut
-$347K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$2K -$42K -76 -96%
NDSI
52
Newman Dignan & Sheerar Inc
Rhode Island
$26 +$6.08K +11 +35%
6CM
53
683 Capital Management
New York
– -$2.73M -4,488 Closed
Man Group
54
Man Group
United Kingdom
– -$472K -776 Closed
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
– -$99K -162 Closed
Walleye Capital
56
Walleye Capital
New York
– -$96K -159 Closed
CSS
57
Cubist Systematic Strategies
Connecticut
– -$92K -150 Closed
BCM
58
Bayesian Capital Management
New York
– -$51K -84 Closed
TCBWMS
59
Texas Capital Bank Wealth Management Services
Texas
– -$34K -56 Closed
VF
60
Virtu Financial
New York
– -$31K -51 Closed
Squarepoint
61
Squarepoint
New York
– -$27K -44 Closed
HF
62
HRT Financial
New York
– -$17K -29 Closed
KAS
63
Kestra Advisory Services
Texas
– -$15K -24 Closed
TRCT
64
Tower Research Capital (TRC)
New York
– -$9K -14 Closed
HWM
65
HighMark Wealth Management
Minnesota
– -$6K -10 Closed
1 2
3

APTO Hedge Fund Activity: Q1 2022 in Review

52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q1 2022, worth a combined $39M — down 8.5% from $42.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of APTO and 7 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was Sanders Morris Harris, adding an estimated $468K. The largest seller was 683 Capital Management, exiting entirely with an estimated $2.73M sold.

  • 52 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q1 2022, down from 58 in Q4 2021.
  • Funds reported $39M of Aptose Biosciences, Inc. stock for Q1 2022, down 8.5% quarter-over-quarter.
  • 7 funds opened new Aptose Biosciences, Inc. positions in Q1 2022 and 13 closed out, a net change of -6 holders.
  • The largest Aptose Biosciences, Inc. buyer in Q1 2022 was Sanders Morris Harris, an estimated $468K added.
  • The largest Aptose Biosciences, Inc. seller in Q1 2022 was 683 Capital Management, an estimated $2.73M sold.

Based on aggregated 13F filings for Q1 2022.